Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor

Leonard B. Saltz, Neal J. Meropol, Patrick Loehrer, Michael N. Needle, Justin Kopit, Robert J. Mayer

Research output: Contribution to journalArticle

1520 Citations (Scopus)

Abstract

Purpose: To evaluate the antitumor activity and toxicity of single-agent cetuximab in patients with chemotherapy-refractory colorectal cancer whose tumors express the epidermal growth factor receptor. Patients and Methods: Phase II, open-label clinical trial. Patients were required to have EGFr expression demonstrated on formalin-fixed paraffin-embedded tumor tissue by immunohistochemical staining before study participation. Patients were required to have received irinotecan, either alone or in a combination regimen, and to have demonstrated clinical failure on this regimen before study entry. Cetuximab was administered weekly by intravenous infusion. The first dose of 400 mg/m2 was given during the course of 2 hours. Subsequent weekly treatments were given at a dose of 250 mg/m2 during the course of 1 hour. Results: Fifty-seven eligible patients were treated. All were assessable for toxicity and response. The most commonly encountered grade 3 to 4 adverse events, regardless of relationship to study drug, were an acne-like skin rash, predominantly on the face and upper torso (86% with any grade; 18% with grade 3), and a composite of asthenia, fatigue, malaise, or lethargy (56% with any grade, 9% with grade 3). Two patients (3.5%) experienced grade 3 allergic reactions requiring discontinuation of study treatment. A third patient experienced a grade 3 allergic reaction that resolved, and the patient continued on the study. Neither diarrhea nor neutropenia were dose limiting in any of the 57 patients treated. Five patients (9%; 95% CI, 3% to 19%) achieved a partial response. Twenty-one additional patients had stable disease or minor responses. The median survival in these previously treated patients with chemotherapy-refractory colorectal cancer is 6.4 months. Conclusion: Cetuximab on this once-weekly schedule has modest activity and is well-tolerated as a single agent in patients with chemotherapy-refractory colorectal cancer whose tumors express the epidermal growth factor receptor. Further studies of cetuximab will evaluate the use of cetuximab in conjunction with first-line and adjuvant treatments for this disease.

Original languageEnglish (US)
Pages (from-to)1201-1208
Number of pages8
JournalJournal of Clinical Oncology
Volume22
Issue number7
DOIs
StatePublished - 2004
Externally publishedYes

Fingerprint

Epidermal Growth Factor Receptor
Colorectal Neoplasms
irinotecan
Drug Therapy
Cetuximab
Hypersensitivity
Asthenia
Torso
Neoplasms
Lethargy
Acne Vulgaris
Proxy
Exanthema
Neutropenia
Intravenous Infusions
Paraffin
Formaldehyde
Fatigue
Diarrhea
Appointments and Schedules

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. / Saltz, Leonard B.; Meropol, Neal J.; Loehrer, Patrick; Needle, Michael N.; Kopit, Justin; Mayer, Robert J.

In: Journal of Clinical Oncology, Vol. 22, No. 7, 2004, p. 1201-1208.

Research output: Contribution to journalArticle

Saltz, Leonard B. ; Meropol, Neal J. ; Loehrer, Patrick ; Needle, Michael N. ; Kopit, Justin ; Mayer, Robert J. / Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. In: Journal of Clinical Oncology. 2004 ; Vol. 22, No. 7. pp. 1201-1208.
@article{0ea54fc625ab46ce950d3e2b701d1707,
title = "Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor",
abstract = "Purpose: To evaluate the antitumor activity and toxicity of single-agent cetuximab in patients with chemotherapy-refractory colorectal cancer whose tumors express the epidermal growth factor receptor. Patients and Methods: Phase II, open-label clinical trial. Patients were required to have EGFr expression demonstrated on formalin-fixed paraffin-embedded tumor tissue by immunohistochemical staining before study participation. Patients were required to have received irinotecan, either alone or in a combination regimen, and to have demonstrated clinical failure on this regimen before study entry. Cetuximab was administered weekly by intravenous infusion. The first dose of 400 mg/m2 was given during the course of 2 hours. Subsequent weekly treatments were given at a dose of 250 mg/m2 during the course of 1 hour. Results: Fifty-seven eligible patients were treated. All were assessable for toxicity and response. The most commonly encountered grade 3 to 4 adverse events, regardless of relationship to study drug, were an acne-like skin rash, predominantly on the face and upper torso (86{\%} with any grade; 18{\%} with grade 3), and a composite of asthenia, fatigue, malaise, or lethargy (56{\%} with any grade, 9{\%} with grade 3). Two patients (3.5{\%}) experienced grade 3 allergic reactions requiring discontinuation of study treatment. A third patient experienced a grade 3 allergic reaction that resolved, and the patient continued on the study. Neither diarrhea nor neutropenia were dose limiting in any of the 57 patients treated. Five patients (9{\%}; 95{\%} CI, 3{\%} to 19{\%}) achieved a partial response. Twenty-one additional patients had stable disease or minor responses. The median survival in these previously treated patients with chemotherapy-refractory colorectal cancer is 6.4 months. Conclusion: Cetuximab on this once-weekly schedule has modest activity and is well-tolerated as a single agent in patients with chemotherapy-refractory colorectal cancer whose tumors express the epidermal growth factor receptor. Further studies of cetuximab will evaluate the use of cetuximab in conjunction with first-line and adjuvant treatments for this disease.",
author = "Saltz, {Leonard B.} and Meropol, {Neal J.} and Patrick Loehrer and Needle, {Michael N.} and Justin Kopit and Mayer, {Robert J.}",
year = "2004",
doi = "10.1200/JCO.2004.10.182",
language = "English (US)",
volume = "22",
pages = "1201--1208",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "7",

}

TY - JOUR

T1 - Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor

AU - Saltz, Leonard B.

AU - Meropol, Neal J.

AU - Loehrer, Patrick

AU - Needle, Michael N.

AU - Kopit, Justin

AU - Mayer, Robert J.

PY - 2004

Y1 - 2004

N2 - Purpose: To evaluate the antitumor activity and toxicity of single-agent cetuximab in patients with chemotherapy-refractory colorectal cancer whose tumors express the epidermal growth factor receptor. Patients and Methods: Phase II, open-label clinical trial. Patients were required to have EGFr expression demonstrated on formalin-fixed paraffin-embedded tumor tissue by immunohistochemical staining before study participation. Patients were required to have received irinotecan, either alone or in a combination regimen, and to have demonstrated clinical failure on this regimen before study entry. Cetuximab was administered weekly by intravenous infusion. The first dose of 400 mg/m2 was given during the course of 2 hours. Subsequent weekly treatments were given at a dose of 250 mg/m2 during the course of 1 hour. Results: Fifty-seven eligible patients were treated. All were assessable for toxicity and response. The most commonly encountered grade 3 to 4 adverse events, regardless of relationship to study drug, were an acne-like skin rash, predominantly on the face and upper torso (86% with any grade; 18% with grade 3), and a composite of asthenia, fatigue, malaise, or lethargy (56% with any grade, 9% with grade 3). Two patients (3.5%) experienced grade 3 allergic reactions requiring discontinuation of study treatment. A third patient experienced a grade 3 allergic reaction that resolved, and the patient continued on the study. Neither diarrhea nor neutropenia were dose limiting in any of the 57 patients treated. Five patients (9%; 95% CI, 3% to 19%) achieved a partial response. Twenty-one additional patients had stable disease or minor responses. The median survival in these previously treated patients with chemotherapy-refractory colorectal cancer is 6.4 months. Conclusion: Cetuximab on this once-weekly schedule has modest activity and is well-tolerated as a single agent in patients with chemotherapy-refractory colorectal cancer whose tumors express the epidermal growth factor receptor. Further studies of cetuximab will evaluate the use of cetuximab in conjunction with first-line and adjuvant treatments for this disease.

AB - Purpose: To evaluate the antitumor activity and toxicity of single-agent cetuximab in patients with chemotherapy-refractory colorectal cancer whose tumors express the epidermal growth factor receptor. Patients and Methods: Phase II, open-label clinical trial. Patients were required to have EGFr expression demonstrated on formalin-fixed paraffin-embedded tumor tissue by immunohistochemical staining before study participation. Patients were required to have received irinotecan, either alone or in a combination regimen, and to have demonstrated clinical failure on this regimen before study entry. Cetuximab was administered weekly by intravenous infusion. The first dose of 400 mg/m2 was given during the course of 2 hours. Subsequent weekly treatments were given at a dose of 250 mg/m2 during the course of 1 hour. Results: Fifty-seven eligible patients were treated. All were assessable for toxicity and response. The most commonly encountered grade 3 to 4 adverse events, regardless of relationship to study drug, were an acne-like skin rash, predominantly on the face and upper torso (86% with any grade; 18% with grade 3), and a composite of asthenia, fatigue, malaise, or lethargy (56% with any grade, 9% with grade 3). Two patients (3.5%) experienced grade 3 allergic reactions requiring discontinuation of study treatment. A third patient experienced a grade 3 allergic reaction that resolved, and the patient continued on the study. Neither diarrhea nor neutropenia were dose limiting in any of the 57 patients treated. Five patients (9%; 95% CI, 3% to 19%) achieved a partial response. Twenty-one additional patients had stable disease or minor responses. The median survival in these previously treated patients with chemotherapy-refractory colorectal cancer is 6.4 months. Conclusion: Cetuximab on this once-weekly schedule has modest activity and is well-tolerated as a single agent in patients with chemotherapy-refractory colorectal cancer whose tumors express the epidermal growth factor receptor. Further studies of cetuximab will evaluate the use of cetuximab in conjunction with first-line and adjuvant treatments for this disease.

UR - http://www.scopus.com/inward/record.url?scp=2142641698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2142641698&partnerID=8YFLogxK

U2 - 10.1200/JCO.2004.10.182

DO - 10.1200/JCO.2004.10.182

M3 - Article

VL - 22

SP - 1201

EP - 1208

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 7

ER -